Virtify and Huron Life Sciences to offer clinical trial disclosure solutions
Virtify, a provider of structured content management software solutions for life sciences, and Huron Consulting Group’s Life Sciences practice have formed an alliance to address the growing challenges with clinical trials registration and results disclosure.
Many pharmaceutical companies and academic and research organizations manage clinical trial disclosure manually. Due to the large number of disparate, investigator-driven studies at these institutions, coupled with constant updates to these studies and compliance challenges with increasingly complex disclosure requirements, using these manual processes has become cumbersome and often error-prone.
“Huron Life Sciences’ unique position in the academic and research marketplace makes this alliance very synergistic for both parties. Virtify CTRR will help these institutions automate compliance of a very de-centralized set of processes, allowing them to become fully compliant in their disclosures,” said Satish Tadikonda, president and CEO, Virtify.
Virtify and Huron will offer these organizations Virtify’s CTRR (Clinical Trial Registration & Results) software, which streamlines and automates the mandatory registration and results disclosure postings to the clinicaltrials.gov web site and to other international registries. The software also has the ability to provide a compliance view across all studies at an institution, allowing for better reporting and proactive compliance. Huron’s extensive experience supporting academic and research institutions in managing complex clinical trials and regulatory compliance will aid the pair’s alliance.
"Clients looking to improve the quality and timing of their disclosures to regulatory authorities can now combine the robust technology of Virtify and the deep expertise of Huron Life Sciences in addressing clinical trial disclosure," said Matthew Lester, managing director, Huron Life Sciences. "Using our combined strengths will not only help these institutions improve compliance, but will continue to allow their trial results to be published in industry medical journals.”